Page 47 - JCTR-10-1

Gonda et al. | Journal of Clinical and Translational Research 2024; 10(1): 33-51 43
for the treatment of COVID-19. Drugs Today (Barc). 3. WHO updates its treatment guidelines to include
2022 Jul;58(7):335-350. molnupiravir, 3 March 2022 News release Geneva, https://
2. Johnson MG, Puenpatom A, Moncada PA, Burgess L, www.who.int/news/item/03-03-2022-molnupiravir
Duke ER, Ohmagari N, Wolf T, Bassetti M, Bhagani S, 4. Fact sheet for healthcare providers: emergency use
Ghosn J, Zhang Y, Wan H, Williams-Diaz A, Brown ML, authorization for molnupiravir. 2021. Available at:
Paschke A, De Anda C. Effect of Molnupiravir on https://www.fda.gov/media/155054/download
Biomarkers, Respiratory Interventions, and Medical Services 5. COVID-19 Treatment Guidelines, Molnupiravir
in COVID-19: A Randomized, Placebo-Controlled Trial. https://www.covid19treatmentguidelines.nih.gov/therapies/
Ann Intern Med. 2022:M22-0729. Online ahead of print. antiviral-therapy/molnupiravir

Supplementary Data 2

Table 1. Baseline levels of blood biomarkers on admission, 5 days, and 14 days after starting treatment for infection in molnupiravir alone, molnupiravir
plus clarithromycin (CAM), and unaffected groups
Blood biomarkers Admission Day 5 P‑value 1 Day 14 P‑value 2
Biochemistry biomarkers
LDH (IU/L)
Molnupiravir 193.1±41.2 250.2±107.3 <0.05 196.7±48.4 n.s.
Molnupiravir + CAM 187.7±50.7 206.7±67.3 n.s. 183.7±55.3 n.s.
Uninfected 186.5±33.5 173.1±45.2 n.s. 172.5±36.4 n.s.
P-value* n.s. <0.05 P-value** n.s.
Total cholesterol (mg/dl)
Molnupiravir 163±41.1 123.7±37.9 <0.05 145.2±35.9 n.s.
Molnupiravir + CAM 158.0±32.5 135.7±40.4 n.s. 158.2±30.2 n.s.
Uninfected 158.6±34.0 157.7±20.0 n.s. 157.2±31.0 n.s.
P-value* n.s. n.s. P-value** n.s.
Triglyceride (mg/dl)
Molnupiravir 118.8±33.5 68.3±21.5 <0.05 96.1±46.2 n.s.
Molnupiravir + CAM 107.5±49.8 71.6±14.9 n.s. 103.9±74.4 n.s.
Uninfected 101.3±47.8 103.4±55.0 n.s. 101.8±41.5 n.s.
P-value* n.s. n.s. P-value** n.s.
Uric acid (mg/dl)
Molnupiravir 4.6±1.4 3.0±1.5 <0.05 4.0±1.5 n.s.
Molnupiravir + CAM 4.5±1.8 3.7±1.1 n.s. 4.5±1.6 n.s.
Uninfected 5.1±1.6 5.0±1.3 n.s. 5±1.5 n.s.
P-value* n.s. n.s. P-value** n.s.
Creatinine (mg/dl)
Molnupiravir 0.78±0.31 0.91±0.27 n.s. 0.79±0.32 n.s.
Molnupiravir + CAM 0.75±0.39 0.79±0.30 n.s. 0.77±0.44 n.s.
Uninfected 0.70±0.26 0.72±0.36 n.s. 0.72±0.32 n.s.
P-value* n.s. n.s. P-value** n.s.
Potassium (mEq/l)
Molnupiravir 3.9±0.5 4.5±0.7 <0.05 3.8±0.6 n.s.
Molnupiravir + CAM 4.0±0.3 4.1±0.4 n.s. 3.9±0.4 n.s.
Uninfected 4.1±0.4 4.1±0.6 n.s. 4.0±0.5 n.s.
P-value* n.s. <0.05 P-value** n.s.
Blood routine biomarkers
WBC (×10 /μl)
2
Molnupiravir 73.2±20.7 96.4±22.5 <0.05 76.0±19.3 n.s.
(Contd...)

DOI: https://doi.org/10.36922/jctr.00075